DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

NCT02252653 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1010

Last updated 2016-07-20

No results posted yet for this study

Summary

The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

Conditions

  • Familial Amyloidotic Cardiomyopathy (FAC)

Sponsors & Collaborators

Principal Investigators

  • Jared Gollob, MD · Alnylam Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • United States
  • Belgium
  • Brazil
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252653 on ClinicalTrials.gov